RT Journal Article
T1 Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study).
A1 Solis-Hernandez, Mª Pilar
A1 Fernandez Del Valle, Ana
A1 Carmona-Bayonas, Alberto
A1 Garcia-Carbonero, Rocio
A1 Custodio, Ana
A1 Benavent, Marta
A1 Alonso Gordoa, Teresa
A1 Nuñez-Valdovino, Bárbara
A1 Sanchez Canovas, Manuel
A1 Matos, Ignacio
A1 Alonso, Vicente
A1 Lopez, Carlos
A1 Viudez, Antonio
A1 Izquierdo, Marta
A1 Calvo-Temprano, David
A1 Grande, Enrique
A1 Capdevila, Jaume
A1 Jimenez-Fonseca, Paula
AB The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression. One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival. Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.
YR 2019
FD 2019-09-03
LK http://hdl.handle.net/10668/14466
UL http://hdl.handle.net/10668/14466
LA en
DS RISalud
RD Apr 11, 2025